Download PDF
Semin Respir Crit Care Med 2017; 38(03): 346-358
DOI: 10.1055/s-0037-1602715
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

New Strategies Targeting Virulence Factors of Staphylococcus aureus and Pseudomonas aeruginosa

Bruno François
1   Intensive Care Unit/CIC-1435, University Hospital of Limoges, Limoges, France
,
Charles-Edouard Luyt
2   Medical Intensive Care Unit, Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Paris, France, and Sorbonne Universités, UPMC Université Paris 06, INSERM, UMRS_1166-ICAN Institute of Cardiometabolism and Nutrition, Paris, France
,
C. Kendall Stover
3   Research and Development, Research Infectious Disease, MedImmune, Gaithersburg, Maryland
,
Jeffery O. Brubaker
4   Scientific Publications, Medical Communications, MedImmune, Gaithersburg, Maryland
,
Jean Chastre
5   Service de Réanimation Médicale, Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75651 Paris Cedex 13, France
,
Hasan S. Jafri
6   Clinical Development, Infectious Disease and Vaccines, MedImmune, Gaithersburg, Maryland
› Author Affiliations
Further Information

Publication History

Publication Date:
04 June 2017 (online)

    Permissions and Reprints

Abstract

Morbidity, mortality, and economic burden of nosocomial pneumonia caused by Staphylococcus aureus and Pseudomonas aeruginosa remain high in mechanically ventilated and hospitalized patients despite the use of empirical antibiotic therapy or antibiotics against specific classes of pathogens and procedures to reduce nosocomial infections in hospital settings. Newer agents that neutralize or inhibit specific S. aureus or P. aeruginosa virulence factors may eliminate or reduce the risk for developing pneumonia before or during mechanical ventilation and may improve patient outcomes through mechanisms that differ from those of antibiotics. In this article, we review the types, mechanisms of action, potential advantages, and stage of development of antivirulence agents (AVAs) that hold promise as alternative preventive or interventional therapies against S. aureus– and P. aeruginosa–associated nosocomial pneumonias. We also present and discuss challenges to the effective utilization of AVAs separately from or in addition to antibiotics and the design of clinical trials and meaningful study end points.

Keywords

antivirulence agents - Staphylococcus aureus - Pseudomonas aeruginosa - nosocomial pneumonia - ventilator-associated pneumonia
 

  • References

  • 1 Kollef MH, Chastre J, Fagon JY. , et al. Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas aeruginosa . Crit Care Med 2014; 42 (10) 2178-2187
    CrossrefPubMedGoogle Scholar
  • 2 Ding S, Kilickaya O, Senkal S, Gajic O, Hubmayr RD, Li G. Temporal trends of ventilator-associated pneumonia incidence and the effect of implementing health-care bundles in a suburban community. Chest 2013; 144 (05) 1461-1468
    CrossrefPubMedGoogle Scholar
  • 3 Koulenti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. Eur J Clin Microbiol Infect Dis 2016 DOI: 10.1007/s10096-016-2703-z
    CrossrefPubMedGoogle Scholar
  • 4 Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 2013; 19 (03) 216-228
    CrossrefPubMedGoogle Scholar
  • 5 Blot S, Koulenti D, Dimopoulos G. , et al; EU-VAP Study Investigators. Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, old, and very old critically ill patients. Crit Care Med 2014; 42 (03) 601-609
    CrossrefPubMedGoogle Scholar
  • 6 Napolitano LM. Use of severity scoring and stratification factors in clinical trials of hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis 2010; 51 (Suppl. 01) S67-S80
    CrossrefPubMedGoogle Scholar
  • 7 Kalanuria AA, Ziai W, Mirski M. Ventilator-associated pneumonia in the ICU. Crit Care 2014; 18 (02) 208
    CrossrefPubMedGoogle Scholar
  • 8 Sulis CA, Walkey AJ, Abadi Y, Campbell Reardon C, Joyce-Brady M. Outcomes of a ventilator-associated pneumonia bundle on rates of ventilator-associated pneumonia and other health care-associated infections in a long-term acute care hospital setting. Am J Infect Control 2014; 42 (05) 536-538
    CrossrefPubMedGoogle Scholar
  • 9 Estella A, Álvarez-Lerma F. Should the diagnosis of ventilator associated pneumonia be improved? [in Spanish]. Med Intensiva 2011; 35 (09) 578-582
    CrossrefPubMedGoogle Scholar
  • 10 Metersky ML, Wang Y, Klompas M, Eckenrode S, Bakullari A, Eldridge N. Trend in ventilator-associated pneumonia rates between 2005 and 2013. JAMA 2016; 316 (22) 2427-2429
    CrossrefPubMedGoogle Scholar
  • 11 Klompas M. Complications of mechanical ventilation--the CDC's new surveillance paradigm. N Engl J Med 2013; 368 (16) 1472-1475
    CrossrefPubMedGoogle Scholar
  • 12 Wuerth BA, Bonnewell JP, Wiemken TL, Arnold FW. Trends in pneumonia mortality rates and hospitalizations by organism, United States, 2002-2011(1). Emerg Infect Dis 2016; 22 (09) 1624-1627
    CrossrefPubMedGoogle Scholar
  • 13 Neidell MJ, Cohen B, Furuya Y. , et al. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis 2012; 55 (06) 807-815
    CrossrefPubMedGoogle Scholar
  • 14 Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010; 51 (Suppl. 01) S81-S87
    CrossrefPubMedGoogle Scholar
  • 15 Kyaw MH, Kern DM, Zhou S, Tunceli O, Jafri HS, Falloon J. Healthcare utilization and costs associated with S. aureus and P. aeruginosa pneumonia in the intensive care unit: a retrospective observational cohort study in a US claims database. BMC Health Serv Res 2015; 15: 241
    CrossrefPubMedGoogle Scholar
  • 16 Heister T, Kaier K, Wolkewitz M. Estimating the burden of nosocomial infections: time dependency and cost clustering should be taken into account. Am J Infect Control 2017; 45 (01) 94-95
    CrossrefPubMedGoogle Scholar
  • 17 Barnett AG, Beyersmann J, Allignol A, Rosenthal VD, Graves N, Wolkewitz M. The time-dependent bias and its effect on extra length of stay due to nosocomial infection. Value Health 2011; 14 (02) 381-386
    CrossrefPubMedGoogle Scholar
  • 18 Czaplewski L, Bax R, Clokie M. , et al. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis 2016; 16 (02) 239-251
    CrossrefPubMedGoogle Scholar
  • 19 Cohen TS, Hilliard JJ, Jones-Nelson O. , et al. Staphylococcus aureus α toxin potentiates opportunistic bacterial lung infections. Sci Transl Med 2016; 8 (329) 329ra31
    CrossrefPubMedGoogle Scholar
  • 20 Park DR. The microbiology of ventilator-associated pneumonia. Respir Care 2005; 50 (06) 742-763 , discussion 763–765
    PubMedGoogle Scholar
  • 21 Kalil AC, Metersky ML, Klompas M. , et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63 (05) e61-e111
    CrossrefPubMedGoogle Scholar
  • 22 Arvanitis M, Anagnostou T, Kourkoumpetis TK, Ziakas PD, Desalermos A, Mylonakis E. The impact of antimicrobial resistance and aging in VAP outcomes: experience from a large tertiary care center. PLoS One 2014; 9 (02) e89984
    CrossrefPubMedGoogle Scholar
  • 23 World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva, Switzerland; 2014
    PubMedGoogle Scholar
  • 24 Torres A, Ewig S, Lode H, Carlet J. ; European HAP working group. Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med 2009; 35 (01) 9-29
    CrossrefPubMedGoogle Scholar
  • 25 Hidron AI, Edwards JR, Patel J. , et al; National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29 (11) 996-1011
    CrossrefPubMedGoogle Scholar
  • 26 Niederman MS. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis 2006; 42 (Suppl 2): S72-S81
    CrossrefPubMedGoogle Scholar
  • 27 Public Health Agency of Canada. Canadian Antimicrobial Resistance Surveillance System Report 2016 . Available at https://www.canada.ca/en/public-health/services/publications/drugs-health-products/canadian-antimicrobial-resistance-surveillance-system-report-2016.html . Accessed on May 18, 2017
    PubMed
  • 28 Ahmed NH, Hussain T, Biswal I. Antimicrobial resistance of bacterial isolates from respiratory secretions of ventilated patients in a multi-specialty hospital. Avicenna J Med 2015; 5 (03) 74-78
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Wilke M, Grube R. Update on management options in the treatment of nosocomial and ventilator assisted pneumonia: review of actual guidelines and economic aspects of therapy. Infect Drug Resist 2013; 7: 1-7
    CrossrefPubMedGoogle Scholar
  • 30 Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 2004; 39 (02) 219-226
    CrossrefPubMedGoogle Scholar
  • 31 Planquette B, Timsit JF, Misset BY. , et al; OUTCOMEREA Study Group. Pseudomonas aeruginosa ventilator-associated pneumonia. predictive factors of treatment failure. Am J Respir Crit Care Med 2013; 188 (01) 69-76
    CrossrefPubMedGoogle Scholar
  • 32 Schubert AM, Sinani H, Schloss PD, Fraser CM. Antibiotic-induced alterations of the murine gut microbiota and subsequent effects on colonization resistance against Clostridium difficile . MBio 2015; 6 (04) e00974
    PubMedGoogle Scholar
  • 33 Castanheira M, Griffin MA, Deshpande LM, Mendes RE, Jones RN, Flamm RK. Detection of mcr-1 among Escherichia coli clinical isolates collected worldwide as part of the SENTRY Antimicrobial Surveillance Program in 2014 and 2015. Antimicrob Agents Chemother 2016; 60 (09) 5623-5624
    CrossrefPubMedGoogle Scholar
  • 34 Baggs J, Fridkin SK, Pollack LA, Srinivasan A, Jernigan JA. Estimating National Trends in Inpatient Antibiotic Use Among US Hospitals From 2006 to 2012. JAMA Intern Med 2016; 176 (11) 1639-1648
    CrossrefPubMedGoogle Scholar
  • 35 Francino MP. Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances. Front Microbiol 2016; 6: 1543
    PubMedGoogle Scholar
  • 36 Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science 2016; 352 (6285): 535-538
    CrossrefPubMedGoogle Scholar
  • 37 Yayan J, Ghebremedhin B, Rasche K. Antibiotic resistance of Pseudomonas aeruginosa in pneumonia at a single university hospital center in Germany over a 10-year period. PLoS One 2015; 10 (10) e0139836
    CrossrefPubMedGoogle Scholar
  • 38 Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother 2010; 54 (01) 109-115
    CrossrefPubMedGoogle Scholar
  • 39 Jacobs DM, Shaver A. Prevalence of and outcomes from Staphylococcus aureus pneumonia among hospitalized patients in the United States, 2009-2012. Am J Infect Control 2016; 45 (04) 404-409
    PubMedGoogle Scholar
  • 40 Hauser AR, Mecsas J, Moir DT. Beyond antibiotics: new therapeutic approaches for bacterial infections. Clin Infect Dis 2016; 63 (01) 89-95
    CrossrefPubMedGoogle Scholar
  • 41 Chastre J, Luyt CE. Optimising the duration of antibiotic therapy for ventilator-associated pneumonia. Eur Respir Rev 2007; 16 (103) 40-44
    CrossrefPubMedGoogle Scholar
  • 42 Bäumler AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature 2016; 535 (7610): 85-93
    CrossrefPubMedGoogle Scholar
  • 43 Skinner C, Zhang G, Patfield S, He X. An in vitro combined antibiotic-antibody treatment eliminates toxicity from Shiga toxin-producing Escherichia coli. Antimicrob Agents Chemother 2015; 59 (09) 5435-5444
    CrossrefPubMedGoogle Scholar
  • 44 Nau R, Eiffert H. Minimizing the release of proinflammatory and toxic bacterial products within the host: a promising approach to improve outcome in life-threatening infections. FEMS Immunol Med Microbiol 2005; 44 (01) 1-16
    CrossrefPubMedGoogle Scholar
  • 45 Goscinski G, Lipcsey M, Eriksson M, Larsson A, Tano E, Sjölin J. Endotoxin neutralization and anti-inflammatory effects of tobramycin and ceftazidime in porcine endotoxin shock. Crit Care 2004; 8 (01) R35-R41
    CrossrefPubMedGoogle Scholar
  • 46 Sellman BR, Stover CK. Antibodies for antibacterials. In: Miller AA, Miller PF. , eds. Emerging Trends in Antibacterial Discovery: Answering the Call to Arms. Norfolk, UK: Caister Academic Press; 2011: 345-366
    Google Scholar
  • 47 Vuong C, Yeh AJ, Cheung GY, Otto M. Investigational drugs to treat methicillin-resistant Staphylococcus aureus . Expert Opin Investig Drugs 2016; 25 (01) 73-93
    CrossrefPubMedGoogle Scholar
  • 48 Sause WE, Buckley PT, Strohl WR, Lynch AS, Torres VJ. Antibody-based biologics and their promise to combat Staphylococcus aureus infections. Trends Pharmacol Sci 2016; 37 (03) 231-241
    CrossrefPubMedGoogle Scholar
  • 49 Oleksiewicz MB, Nagy G, Nagy E. Anti-bacterial monoclonal antibodies: back to the future?. Arch Biochem Biophys 2012; 526 (02) 124-131
    CrossrefPubMedGoogle Scholar
  • 50 Lipsitch M, Siber GR. How can vaccines contribute to solving the antimicrobial resistance problem?. MBio 2016; 7 (03) e00428-16
    CrossrefPubMedGoogle Scholar
  • 51 Saylor C, Dadachova E, Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Vaccine 2009; 27 (Suppl 6): G38-G46
    CrossrefPubMedGoogle Scholar
  • 52 Yu XQ, Robbie GJ, Wu Y. , et al. Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-Staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults. Antimicrob Agents Chemother 2016; 61 (01) e01020-16
    PubMedGoogle Scholar
  • 53 DiGiandomenico A, Sellman BR. Antibacterial monoclonal antibodies: the next generation?. Curr Opin Microbiol 2015; 27: 78-85
    CrossrefPubMedGoogle Scholar
  • 54 Hua L, Cohen TS, Shi Y. , et al. MEDI4893 promotes survival and extends the antibiotic treatment window in a Staphylococcus aureus immunocompromised pneumonia model. Antimicrob Agents Chemother 2015; 59 (08) 4526-4532
    CrossrefPubMedGoogle Scholar
  • 55 Henry BD, Neill DR, Becker KA. , et al. Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat Biotechnol 2015; 33 (01) 81-88
    CrossrefPubMedGoogle Scholar
  • 56 Amara N, Krom BP, Kaufmann GF, Meijler MM. Macromolecular inhibition of quorum sensing: enzymes, antibodies, and beyond. Chem Rev 2011; 111 (01) 195-208
    CrossrefPubMedGoogle Scholar
  • 57 Paulander W, Nissen Varming A, Bæk KT, Haaber J, Frees D, Ingmer H. Antibiotic-mediated selection of quorum-sensing-negative Staphylococcus aureus . MBio 2013; 3 (06) e00459-e12
    PubMedGoogle Scholar
  • 58 Tal-Gan Y, Ivancic M, Cornilescu G, Blackwell HE. Characterization of structural elements in native autoinducing peptides and non-native analogues that permit the differential modulation of AgrC-type quorum sensing receptors in Staphylococcus aureus . Org Biomol Chem 2016; 14 (01) 113-121
    CrossrefPubMedGoogle Scholar
  • 59 Guo Q, Wei Y, Xia B. , et al. Identification of a small molecule that simultaneously suppresses virulence and antibiotic resistance of Pseudomonas aeruginosa . Sci Rep 2016; 6: 19141
    CrossrefPubMedGoogle Scholar
  • 60 François B. New targets for new therapeutic approaches. Crit Care 2014; 18 (06) 669
    CrossrefPubMedGoogle Scholar
  • 61 Swatton JE, Davenport PW, Maunders EA, Griffin JL, Lilley KS, Welch M. Impact of azithromycin on the quorum sensing-controlled proteome of Pseudomonas aeruginosa . PLoS One 2016; 11 (01) e0147698
    CrossrefPubMedGoogle Scholar
  • 62 van Delden C, Köhler T, Brunner-Ferber F, François B, Carlet J, Pechère JC. Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Med 2012; 38 (07) 1118-1125
    CrossrefPubMedGoogle Scholar
  • 63 Starkey M, Lepine F, Maura D. , et al. Identification of anti-virulence compounds that disrupt quorum-sensing regulated acute and persistent pathogenicity. PLoS Pathog 2014; 10 (08) e1004321
    CrossrefPubMedGoogle Scholar
  • 64 Kizaki H, Omae Y, Tabuchi F, Saito Y, Sekimizu K, Kaito C. Cell surface phenol-soluble modulins regulate Staphylococcus aureus colony spreading. PLoS One 2016; 11 (10) e0164523
    CrossrefPubMedGoogle Scholar
  • 65 Queck SY, Khan BA, Wang R. , et al. Mobile genetic element-encoded cytolysin connects virulence to methicillin resistance in MRSA. PLoS Pathog 2009; 5 (07) e1000533
    CrossrefPubMedGoogle Scholar
  • 66 Cheung GY, Joo HS, Chatterjee SS, Otto M. Phenol-soluble modulins--critical determinants of staphylococcal virulence. FEMS Microbiol Rev 2014; 38 (04) 698-719
    CrossrefPubMedGoogle Scholar
  • 67 Ghafoor A, Hay ID, Rehm BH. Role of exopolysaccharides in Pseudomonas aeruginosa biofilm formation and architecture. Appl Environ Microbiol 2011; 77 (15) 5238-5246
    CrossrefPubMedGoogle Scholar
  • 68 DiGiandomenico A, Warrener P, Hamilton M. , et al. Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J Exp Med 2012; 209 (07) 1273-1287
    CrossrefPubMedGoogle Scholar
  • 69 Hazenbos WL, Kajihara KK, Vandlen R. , et al. Novel staphylococcal glycosyltransferases SdgA and SdgB mediate immunogenicity and protection of virulence-associated cell wall proteins. PLoS Pathog 2013; 9 (10) e1003653
    CrossrefPubMedGoogle Scholar
  • 70 Rentero Rebollo I, McCallin S, Bertoldo D, Entenza JM, Moreillon P, Heinis C. Development of potent and selective S. aureus sortase A inhibitors based on peptide macrocycles. ACS Med Chem Lett 2016; 7 (06) 606-611
    CrossrefPubMedGoogle Scholar
  • 71 Aridis Pharmaceuticals Press Release. AR-301: fully human mAb against Staphylococcus aureus. Available at: http://www.aridispharma.com/ar301.html . Accessed March 16, 2017
    PubMedGoogle Scholar
  • 72 Oganesyan V, Peng L, Damschroder MM. , et al. Mechanisms of neutralization of a human anti-α-toxin antibody. J Biol Chem 2014; 289 (43) 29874-29880
    CrossrefPubMedGoogle Scholar
  • 73 Tabor DE, Yu L, Mok H. , et al. Staphylococcus aureus alpha-toxin is conserved among diverse hospital respiratory isolates collected from a global surveillance study and is neutralized by monoclonal antibody MEDI4893. Antimicrob Agents Chemother 2016; 60 (09) 5312-5321
    CrossrefPubMedGoogle Scholar
  • 74 Sharma-Kuinkel BK, Wu Y, Tabor DE. , et al. Characterization of alpha-toxin hla gene variants, alpha-toxin expression levels, and levels of antibody to alpha-toxin in hemodialysis and postsurgical patients with Staphylococcus aureus bacteremia. J Clin Microbiol 2015; 53 (01) 227-236
    CrossrefPubMedGoogle Scholar
  • 75 François B, Chastre J, Eggiman P. , et al; The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium. The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: a public-private collaborative effort in designing and performing clinical trials for novel antibacterial drugs to prevent nosocomial pneumonia. Clin Infect Dis 2016; 63 (Suppl 2): S46-S51
    CrossrefPubMedGoogle Scholar
  • 76 Rouha H, Badarau A, Visram ZC. , et al. Five birds, one stone: neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs 2015; 7 (01) 243-254
    CrossrefPubMedGoogle Scholar
  • 77 Diep BA, Le VT, Visram ZC. , et al. Improved protection in a rabbit model of community-associated methicillin-resistant Staphylococcus aureus necrotizing pneumonia upon neutralization of leukocidins in addition to alpha-hemolysin. Antimicrob Agents Chemother 2016; 60 (10) 6333-6340
    CrossrefPubMedGoogle Scholar
  • 78 Arsanis. Programs & pipeline. Available at: http://www.arsanis.com/programs-pipeline . Accessed March 16, 2017
    PubMed
  • 79 XBiotech. S. aureus (Staphylococcus aureus ). Available at: http://xbiotech.com/clinical/s-aureus.php . Accessed March 16, 2017
    PubMed
  • 80 Huynh T, Stecher M, McKinnon J, Jung N, Rupp ME. Safety and tolerability of 514G3, a true human anti-protein A monoclonal antibody for the treatment of S. aureus bacteremia. Open Forum Infect Dis 2016; 3 (Suppl 1): 1354
    PubMedGoogle Scholar
  • 81 François B, Luyt CE, Dugard A. , et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med 2012; 40 (08) 2320-2326
    CrossrefPubMedGoogle Scholar
  • 82 KaloBios Pharmaceuticals Press Release. KaloBios reports top-line data for phase 2 study of KB001-A to treat Pseudomonas aeruginosa lung infections in cystic fibrosis patients. 2015 . Available at: http://content.equisolve.net/kalobios/news/2015-01-06_KaloBios_Reports_Top_Line_Data_for_Phase_2_Study_52.pdf . Accessed March 16, 2017
    PubMedGoogle Scholar
  • 83 Warrener P, Varkey R, Bonnell JC. , et al. A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models. Antimicrob Agents Chemother 2014; 58 (08) 4384-4391
    CrossrefPubMedGoogle Scholar
  • 84 DiGiandomenico A, Keller AE, Gao C. , et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa . Sci Transl Med 2014; 6 (262) 262ra155
    CrossrefPubMedGoogle Scholar
  • 85 Aridis Pharmaceuticals Press Release. Aridis Pharmaceuticals reports positive clinical data from phase 1/2 study of human monoclonal antibody AR-301 for treating pneumonia. 2017 . Available at: http://www.aridispharma.com/Aridis%20-%20AR301%20data%20-%201.4.16.pdf . Accessed March 16, 2017
    PubMedGoogle Scholar
  • 86 Lazar H, Horn MP, Zuercher AW. , et al. Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. Antimicrob Agents Chemother 2009; 53 (08) 3442-3446
    CrossrefPubMedGoogle Scholar
  • 87 Que YA, Lazar H, Wolff M. , et al. Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis 2014; 33 (10) 1861-1867
    CrossrefPubMedGoogle Scholar
  • 88 Schuch R, Lee HM, Schneider BC. , et al. Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia. J Infect Dis 2014; 209 (09) 1469-1478
    CrossrefPubMedGoogle Scholar
  • 89 Cassino C, Murphy MG, Boyle J, Rotolo J, Wittekind M. Results of the first in human study of lysin CF-301 evaluating the safety, tolerability and pharmacokinetic profile in healthy volunteers. . Eposter EVLB62. Paper presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Amsterdam, The Netherlands; 2016
    PubMedGoogle Scholar
  • 90 Jun SY, Jung GM, Yoon SJ. , et al. Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient. Antimicrob Agents Chemother 2014; 58 (04) 2084-2088
    CrossrefPubMedGoogle Scholar
  • 91 Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009; 34 (04) 349-357
    CrossrefPubMedGoogle Scholar
  • 92 Pherecydes Pharma. Bacteriophages, a promising [sic] therapy. 2017 . Available at: http://www.pherecydes-pharma.com/pneumophage.html . Accessed March 16, 2017
    PubMedGoogle Scholar
  • 93 Micek ST, Wunderink RG, Kollef MH. , et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit Care 2015; 19: 219
    CrossrefPubMedGoogle Scholar
  • 94 Huang ZG, Zheng XZ, Guan J, Xiao SN, Zhuo C. Direct detection of methicillin-resistant Staphylococcus aureus in sputum specimens from patients with hospital-associated pneumonia using a novel multilocus PCR assay. Pathogens 2015; 4 (02) 199-209
    CrossrefPubMedGoogle Scholar
  • 95 Koch H, Emrich T, Jampen S. , et al. Development of a 4-valent genotyping assay for direct identification of the most frequent Pseudomonas aeruginosa serotypes from respiratory specimens of pneumonia patients. J Med Microbiol 2014; 63 (Pt 4): 508-517
    CrossrefPubMedGoogle Scholar
  • 96 Metzger S, Frobel RA, Dunne Jr WM. Rapid simultaneous identification and quantitation of Staphylococcus aureus and Pseudomonas aeruginosa directly from bronchoalveolar lavage specimens using automated microscopy. Diagn Microbiol Infect Dis 2014; 79 (02) 160-165
    CrossrefPubMedGoogle Scholar
  • 97 Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001; 163 (06) 1371-1375
    CrossrefPubMedGoogle Scholar
  • 98 Kong C, Neoh HM, Nathan S. Targeting Staphylococcus aureus toxins: a potential form of anti-virulence therapy. Toxins (Basel) 2016; 8 (03) E72
    CrossrefPubMedGoogle Scholar
  • 99 Painter KL, Krishna A, Wigneshweraraj S, Edwards AM. What role does the quorum-sensing accessory gene regulator system play during Staphylococcus aureus bacteremia?. Trends Microbiol 2014; 22 (12) 676-685
    CrossrefPubMedGoogle Scholar
  • 100 Houston P, Rowe SE, Pozzi C, Waters EM, O'Gara JP. Essential role for the major autolysin in the fibronectin-binding protein-mediated Staphylococcus aureus biofilm phenotype. Infect Immun 2011; 79 (03) 1153-1165
    CrossrefPubMedGoogle Scholar
  • 101 Kipnis E, Sawa T, Wiener-Kronish J. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect 2006; 36 (02) 78-91
    CrossrefPubMedGoogle Scholar
  • 102 Tkaczyk C, Hamilton MM, Sadowska A. , et al. Targeting alpha toxin and ClfA with a multimechanistic monoclonal-antibody-based approach for prophylaxis of serious Staphylococcus aureus disease. MBio 2016; 7 (03) e00528-16
    CrossrefPubMedGoogle Scholar
  • 103 Lehar SM, Pillow T, Xu M. , et al. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus . Nature 2015; 527 (7578): 323-328
    CrossrefPubMedGoogle Scholar
  • 104 Adhikari RP, Kort T, Shulenin S. , et al. Antibodies to S. aureus LukS-PV attenuated subunit vaccine neutralize a broad spectrum of canonical and non-canonical bicomponent leukotoxin pairs. PLoS One 2015; 10 (09) e0137874
    CrossrefPubMedGoogle Scholar
  • 105 Adhikari RP, Kort T, Shulenin S. , et al. Correction: antibodies to S. aureus LukS-PV attenuated subunit vaccine neutralize a broad spectrum of canonical and non-canonical bicomponent leukotoxin pairs. PLoS One 2015; 10 (11) e0143493
    CrossrefPubMedGoogle Scholar
  • 106 Varrone JJ, de Mesy Bentley KL, Bello-Irizarry SN. , et al. Passive immunization with anti-glucosaminidase monoclonal antibodies protects mice from implant-associated osteomyelitis by mediating opsonophagocytosis of Staphylococcus aureus megaclusters. J Orthop Res 2014; 32 (10) 1389-1396
    CrossrefPubMedGoogle Scholar
  • 107 Sully EK, Whaley K, Bohorova N. , et al. A tripartite cocktail of chimeric monoclonal antibodies passively protects mice against ricin, staphylococcal enterotoxin B and Clostridium perfringens epsilon toxin. Toxicon 2014; 92: 36-41
    CrossrefPubMedGoogle Scholar
  • 108 van den Berg S, Bonarius HP, van Kessel KP. , et al. A human monoclonal antibody targeting the conserved staphylococcal antigen IsaA protects mice against Staphylococcus aureus bacteremia. Int J Med Microbiol 2015; 305 (01) 55-64
    CrossrefPubMedGoogle Scholar
  • 109 Vasquez JK, Tal-Gan Y, Cornilescu G, Tyler KA, Blackwell HE. Simplified AIP-II peptidomimetics are potent inhibitors of Staphylococcus aureus AgrC quorum sensing receptors. ChemBioChem 2017; 18 (04) 413-423
    CrossrefPubMedGoogle Scholar
  • 110 O'Rourke JP, Daly SM, Triplett KD, Peabody D, Chackerian B, Hall PR. Development of a mimotope vaccine targeting the Staphylococcus aureus quorum sensing pathway. PLoS One 2014; 9 (11) e111198
    CrossrefPubMedGoogle Scholar
  • 111 Tetz G, Vikina D, Tetz V. Antimicrobial activity of mul-1867, a novel antimicrobial compound, against multidrug-resistant Pseudomonas aeruginosa . Ann Clin Microbiol Antimicrob 2016; 15: 19
    CrossrefPubMedGoogle Scholar
  • 112 Papareddy P, Kasetty G, Kalle M. , et al. NLF20: an antimicrobial peptide with therapeutic potential against invasive Pseudomonas aeruginosa infection. J Antimicrob Chemother 2016; 71 (01) 170-180
    CrossrefPubMedGoogle Scholar
  • 113 Manzo G, Scorciapino MA, Wadhwani P. , et al. Enhanced amphiphilic profile of a short β-stranded peptide improves its antimicrobial activity. PLoS One 2015; 10 (01) e0116379
    CrossrefPubMedGoogle Scholar
  • 114 Scorciapino MA, Pirri G, Vargiu AV. , et al. A novel dendrimeric peptide with antimicrobial properties: structure-function analysis of SB056. Biophys J 2012; 102 (05) 1039-1048
    CrossrefPubMedGoogle Scholar
  • 115 Gebauer M, Skerra A. Anticalins small engineered binding proteins based on the lipocalin scaffold. Methods Enzymol 2012; 503: 157-188
    PubMedGoogle Scholar
  • 116 Schmidt J, Patora-Komisarska K, Moehle K, Obrecht D, Robinson JA. Structural studies of β-hairpin peptidomimetic antibiotics that target LptD in Pseudomonas sp. Bioorg Med Chem 2013; 21 (18) 5806-5810
    CrossrefPubMedGoogle Scholar